WO2018171279A1 - Application du composé ss-31 pour la préparation d'un médicament pour le traitement de l'athérosclérose et de maladies associées - Google Patents
Application du composé ss-31 pour la préparation d'un médicament pour le traitement de l'athérosclérose et de maladies associées Download PDFInfo
- Publication number
- WO2018171279A1 WO2018171279A1 PCT/CN2017/118835 CN2017118835W WO2018171279A1 WO 2018171279 A1 WO2018171279 A1 WO 2018171279A1 CN 2017118835 W CN2017118835 W CN 2017118835W WO 2018171279 A1 WO2018171279 A1 WO 2018171279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- compound
- aortic
- development
- medicament
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 201000001320 Atherosclerosis Diseases 0.000 title abstract description 32
- 230000003143 atherosclerotic effect Effects 0.000 claims abstract description 17
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims abstract description 9
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 230000004792 oxidative damage Effects 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 claims abstract description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims abstract description 4
- 208000006170 carotid stenosis Diseases 0.000 claims abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 4
- 210000003141 lower extremity Anatomy 0.000 claims abstract description 4
- 238000011161 development Methods 0.000 claims description 22
- 230000018109 developmental process Effects 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 14
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 claims description 11
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 claims description 11
- 230000036542 oxidative stress Effects 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000007505 plaque formation Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 102000049320 CD36 Human genes 0.000 claims 1
- 108010045374 CD36 Antigens Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 37
- 210000002540 macrophage Anatomy 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 230000007423 decrease Effects 0.000 abstract description 8
- 102000008186 Collagen Human genes 0.000 abstract description 4
- 108010035532 Collagen Proteins 0.000 abstract description 4
- 229920001436 collagen Polymers 0.000 abstract description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 4
- 102000013918 Apolipoproteins E Human genes 0.000 description 30
- 108010025628 Apolipoproteins E Proteins 0.000 description 30
- 230000000694 effects Effects 0.000 description 21
- 210000000709 aorta Anatomy 0.000 description 14
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 13
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 210000003291 sinus of valsalva Anatomy 0.000 description 11
- 101100407812 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pas4 gene Proteins 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000000497 foam cell Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 238000009636 ATP test Methods 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000013010 Member 1 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 102000016610 Oxidized LDL Receptors Human genes 0.000 description 1
- 108010028191 Oxidized LDL Receptors Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
Definitions
- the invention belongs to the field of chemical medicine and relates to the application of a compound Szeto-Schiller-31 (SS-31) for preparing a medicament for treating atherosclerotic diseases.
- Atherosclerosis is the pathological basis of cardiovascular disease, including carotid stenosis, lower extremity arteriosclerosis obliterans and coronary heart disease.
- the clinical manifestations and pathological features of these diseases are not the same, but they have the common characteristics: the slow development of the lesions, the narrowing of the lumen of the affected arteries, and the lack of blood supply to the distal tissues. So far, there is no ideal preventive drug, which has become a worldwide cause. The most important cause of human death. At present, the pathogenesis of these diseases is still controversial. Genetic, inflammatory, high-fat diet, aging and other complex factors are the common pathogenic factors of these diseases.
- the pathological mechanisms include vascular endothelial injury and monocyte adhesion migration.
- Atherosclerotic diseases are a serious hazard to human health, which brings great psychological and economic burden to patients, their families and society.
- the development of drugs for the prevention and treatment of atherosclerosis has received much attention.
- AS Arterial endothelial injury is the initial step of AS, and damaged endothelial cells secrete adhesion molecules and cytokines to recruit white blood cells.
- the persistence of inflammation upregulates the expression of macrophage scavenger receptors, increases ox-LDL uptake, and promotes foam cell formation.
- Foam cells are the most prominent inflammatory cells in AS plaques.
- adhesion molecules such as intracellular adhesion molecules, vascular cell adhesion molecules and monocyte chemotactic factors are highly expressed in AS plaques. After adhering to endothelial cells via adhesion molecules, leukocytes are mediated by chemokines and penetrate into the intima of the blood vessels.
- CD36 and LOX-1 are oxidative low-density lipoprotein (ox-LDL) receptors, which are lipoproteins on the surface of macrophages; ABCA1 and ABCG1 are lipoproteins on the surface of macrophages, and cholesterol is excreted and receptor HDL Or apolipoprotein A-I binding.
- Szeto-Schiller-31 (SS-31) is a novel mitochondrial-targeting compound synthesized by Szeto in 2005. It can act on mitochondrial inner membrane cardiolipin to protect mitochondrial integrity in an animal model of renal ischemia. Reduce or inhibit the production of mitochondria-derived reactive oxygen species (ROS), increase the level of adenosine triphosphate (ATP), and reduce oxidative stress. Obviously these findings are not directly related to anti-atherosclerosis. At present, SS-31 has been applied to many human disease models and has shown certain effects.
- ROS mitochondria-derived reactive oxygen species
- ATP adenosine triphosphate
- SS-31 has a protective effect on heart failure and hypertensive cardiomyopathy, although heart failure and hypertensive myocardium
- the disease and the atherosclerotic disease involved in this application are completely different from the pathogenesis of the disease, the pathophysiological basis, the corresponding therapeutic drugs, therapeutic targets and treatment strategies, and it is impossible to give guidance and enlightenment, but we still want to Boldly try to see if SS-31 has a protective effect on atherosclerotic disease.
- the object of the present invention is to discover a new medical use of SS-31 in the preparation of atherosclerosis and related diseases through a disease model associated with atherosclerotic diseases.
- SS-31 is used in an animal model of atherosclerotic disease, and the results show that subcutaneous injection of SS-31 delays the development of mouse AS, blocks the formation of plaque, and stabilizes vulnerable plaque on the other hand.
- SS-31 can reduce the level of aortic ROS in mice, reduce oxidative damage, increase ATP levels, improve systemic inflammation in mice, and decrease the expression of lipid uptake proteins (CD36 and LOX-1) in mouse aortic plaques. These results indicate that SS-31 can be used clinically as a therapeutic drug for AS or related diseases.
- SS-31 itself or its main component is used in the treatment of atherosclerotic diseases including carotid stenosis, lower extremity arteriosclerosis obliterans and coronary heart disease.
- SS-31 itself or its use as a main component in the preparation of the following drugs:
- the present invention is the first to apply the novel mitochondrial-targeting compound SS-31 for the treatment of atherosclerosis and related diseases, and can be used as a new application for preparing drugs for treating atherosclerosis and related diseases, and has a huge market. Value and social benefits.
- the present invention provides the use of SS-31 as a main component of a drug in atherosclerotic diseases.
- SS-31 delays the development of atherosclerotic disease in mice, reduces the formation of plaques, and stabilizes vulnerable plaques.
- FIG. 6 Effect of SS-31 on aortic reactive oxygen species (ROS) in ApoE -/- mice.
- ROS reactive oxygen species
- ApoE -/- mice Male 8-week-old ApoE -/- mice (genetic background: C57BL/6) were purchased from the Institute of Model Animals of Nanjing University. ApoE -/- mice were housed in SPF-class animal rooms and fed a high-fat diet. High-fat diet formula: 0.2% cholesterol and 20% fat mixed with conventional feed. ApoE -/- mice were randomly divided into control group (P), low-dose drug group (M1, 1 mg/kg/d) and high-dose drug group (M3, 3 mg/kg/d), with 30 rats in each group.
- P control group
- M1, 1 mg/kg/d low-dose drug group
- M3, 3 mg/kg/d high-dose drug group
- Group P was injected subcutaneously with 5 mL ⁇ kg -1 ⁇ d -1 saline, and M1 group was injected subcutaneously with SS-31 5 mL ⁇ kg -1 ⁇ d -1 (SS-31 powder was dissolved in physiological saline at a concentration of 0.2 mg ⁇ mL -1 , Shanghai Qiang Yao Biotechnology Co., Ltd. synthesis, dose reference), M3 group subcutaneous injection of SS-31 5mL ⁇ kg -1 ⁇ d -1 (concentration 0.6mg ⁇ mL -1 ).
- mice were anesthetized by intraperitoneal injection of pentobarbital (40 mg ⁇ kg -1 ), blood was taken through the inferior vena cava, the anesthetic dose (80 mg ⁇ kg -1 ) was added, and the neck dislocation was sacrificed, and the heart and aorta were collected.
- Cardiac specimens were fixed in 4% paraformaldehyde for 24 hours, embedded in OCT or embedded in paraffin, and 10 slices of 6 ⁇ m thick paraffin or frozen sections were continuously cut in the microtome. The aortic sinus paraffin sections were stored at room temperature for use.
- TG serum triglyceride
- TC total cholesterol
- Enzyme-linked immunosorbent assay (ELISA) kit detects intracellular adhesion molecule-1 (ICAM-1) and monocyte chemotaxis Factor-1 (Monocyte chemoattractant protein, MCP-1), interleukin (IL-6) and C-reactive protein (CRP) levels.
- ICM-1 intracellular adhesion molecule-1
- MCP-1 monocyte chemotaxis Factor-1
- IL-6 interleukin
- CRP C-reactive protein
- the aorta was embedded in OCT immediately after excision. After cryopreservation, a 6 ⁇ m thick slice was sliced on a glass slide. The fluorescent probe (Dihydroethidium, DHE, 10 ⁇ M, Sigma-Aldrich, USA) was incubated at 37 ° C for 30 min in the dark. Focusing microscope (ZEISS HB050, ZEISS, Germany) observed fluorescence, and fluorescence strongly reacted with ROS levels. Immediately after the aorta was isolated, the ATP level and total SOD activity were measured using the ATP test kit (Shanghai Biyuntian Biotechnology Co., Ltd.) and the SOD test kit (Nanjing Institute of Bioengineering).
- aorta was lysed by lysate (Thermo Fisher Scientific, UK), the protein concentration determined by BCA method, 35 ⁇ g of total protein extract was electrophoresed on a 12% SDS-PAGE gel, and transferred to a nitrocellulose transfer membrane (Nitrocellulose).
- tissue sections of the mice were dewaxed, hematoxylin staining for 4 min, Masson's modified trichrome dyeing for 8 min, bright green staining for 8 min, 0.2% ammonium acetate wash to no dye shedding, dehydration, transparency, sealing, observation under light microscope And take pictures.
- Image J software was used to analyze the amount of collagen (blue) in the plaque.
- mice Tissue sections of mice were dewaxed, antigen-repaired, 3% H 2 O 2 inhibited endogenous peroxidase, primary antibody (1:200 dilution) was incubated for 1.5 h at room temperature, and secondary antibody (1:200 dilution) was incubated for 30 min at room temperature. DAB coloration, hematoxylin counterstaining. After the staining was completed, it was observed under an optical microscope and photographed.
- CD68 macrophage molecular marker
- ⁇ -SMA smooth muscle cell molecular marker
- CD36 antibody was purchased from Proteintech Group, USA
- LOX-1 antibody was purchased from Santa Cruz Biotech, USA
- ABCA1 antibody was purchased from US Signalway Antibody LLC
- secondary antibody goat anti-rabbit or oxygen anti-mouse
- the P group ApoE -/- mice were similar in weight to the administration group (M1 and M3) at 8 and 20 weeks, and the serum TC and TG in the administration group were similar to the P group at 20 weeks, as shown in Table 1.
- Gross aortic red staining of the aorta revealed a significant reduction in plaque area in the ApoE -/- mice of the M1 and M3 groups, as shown in Figure 1, and quantified on the right. Oil red staining of the frozen section of the aortic sinus area showed that the plaque size of the ApoE -/- mice in the M1 and M3 groups was significantly reduced, as shown in Fig. 2, and the quantified map below.
- the plaque composition changes were studied by CD68, ⁇ -SMA immunohistochemistry and Masson special staining. As shown in Fig. 3, the immunohistochemical positive areas of CD68 in M1 and M3 groups were significantly reduced, and the quantitative map was below; Fig. 4 is ⁇ -SMA. Immunohistochemistry showed a significant increase in smooth muscle cells at the plaques of ApoE -/- mice in the M1 and M3 groups, with quantified maps below; Figure 5 is a special staining of Masson, blue area is quantified below, and ApoE -/- is small in M1 and M3 groups. Collagen increased significantly at the plaque of the mouse. The above results indicate that the plaque area of the SS-31 group is significantly reduced and the plaque is more early and more stable. Therefore, SS-31 can be used to block the formation of atherosclerotic plaque and delay the development of AS.
- 2.2SS-31 reduces aortic oxidative stress levels in ApoE -/- mice and increases aortic ATP synthesis
- FIG. 6 is a DHE staining of aortic frozen sections.
- the red positive areas of ApoE -/- mice in the M1 and M3 groups were significantly reduced, indicating a decrease in ROS levels and a decrease in oxidative stress in ApoE -/- mice.
- Aortic ATP results showed a significant increase in aortic ATP levels in the M1 and M3 groups, as shown in Figure 7.
- SOD is the main protein for ROS clearance in cells, including SOD1 in cells and SOD2 in mitochondria.
- SOD2 plays a major role.
- Aortic Western blotting showed no change in SOD2 protein levels, as shown in Figure 8, below which is a quantitative map; but the total aortic SOD activity was significantly increased, as shown in Figure 9.
- Increased ROS levels impair DNA, and 8-OHDG immunohistochemistry was used to detect arterial DNA damage.
- the results showed that the 8-OHDG-positive area of mice in M1 and M3 groups was significantly reduced, as shown in Figure 10, and the upper part was 8-OHDG immunized.
- Histochemical image below is a quantitative map of positive areas. The above results indicate that SS-31 reduces the level of arterial oxidative stress and can therefore be used to reduce aortic oxidative damage and further expansion of atheromatous plaques.
- ICAM-1 and MCP-1 are the major inflammatory factors in AS, promoting the adhesion of monocytes/macrophages to endothelial cells and migration to the inner membrane.
- the serum levels of ICAM-1 and MCP-1 in the M1 and M3 mice were significantly reduced (see Table 1).
- Macrophages that migrate to the endothelium secrete pro-inflammatory factors, including IL-6, IL-1 ⁇ and Tumor necrosis factor alfa (TNF- ⁇ ). These inflammatory factors mediate systemic inflammatory responses, such as activation of acute phase proteins encoded by the liver gene, including CRP and serum amyloid A (SAA).
- Serum IL-6 was significantly decreased in the ApoE -/- mice of the M1 and M3 groups, and CRP was slightly decreased, as shown in Table 1.
- the above results indicate that SS-31 can improve the systemic inflammation level of ApoE -/- mice, which is beneficial to delay the further development of atheroma.
- 2.4SS-31 reduces the expression of aortic lipid uptake protein in ApoE -/- mice
- Foam cell formation is the key to the emergence of early plaques in AS. Excessive intake of Oxidized low-density lipoprotein (ox-LDL), excessive cholesterol esterification, and impaired cholesterol release lead to accumulation of cholesterol esters, formation of lipid droplets, and the cells gradually transform into foam cells.
- CD36 Cluster of differentiation 36
- LOX-1 Lectin-like ox-LDL receptor-1
- ABCA1 ATP-binding cassette A1 is a lipid.
- Excrete protein is a lipid.
- Table 1 mouse body weight and serum lipid index.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une application du composé Szeto-Schiller (SS-31) pour la préparation d'un médicament pour le traitement de l'athérosclérose et de maladies associées, telles que la sténose carotidienne, l'artériopathie oblitérante des membres inférieurs et la coronaropathie. Le composé SS-31 découvert permet de soulager le processus de l'athérosclérose de la manière suivante : réduction sensible du niveau de ROS dans les artères de souris, réduction du stress oxydant, augmentation du niveau d'ATP; réduction sensible de la teneur en macrophages à l'emplacement de la plaque athéromateuse fibreuse, augmentation sensible de la teneur en cellules musculaires lisses et de la teneur en collagène à l'emplacement de la plaque athéromateuse fibreuse et stabilisation de cette dernière; modification senseible du degré d'inflammation; et réduction sensible de l'expression d'une protéine d'absorption de lipide à l'emplacement de la plaque athémorateuse fibreuse. Les résultats ont montré que le SS-31 a une action thérapeutique contre l'athérosclérose et les maladies associées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710186245.1 | 2017-03-24 | ||
CN201710186245.1A CN107041946A (zh) | 2017-03-24 | 2017-03-24 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018171279A1 true WO2018171279A1 (fr) | 2018-09-27 |
Family
ID=59544864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/118835 WO2018171279A1 (fr) | 2017-03-24 | 2017-12-27 | Application du composé ss-31 pour la préparation d'un médicament pour le traitement de l'athérosclérose et de maladies associées |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107041946A (fr) |
WO (1) | WO2018171279A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
EP3771467A1 (fr) * | 2019-07-30 | 2021-02-03 | Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau | Ss-31 pour la prévention et/ou le traitement de l'anévrisme |
CN113143922B (zh) * | 2021-05-07 | 2022-12-20 | 广州医科大学 | Dhc在制备动脉粥样硬化治疗制剂中的应用 |
CN115400201A (zh) * | 2021-05-26 | 2022-11-29 | 四川大学华西医院 | Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途 |
CN113476587B (zh) * | 2021-07-19 | 2022-07-12 | 河南大学 | 一种脑靶向的神经保护剂ss31-ha-rt及其制备方法和应用 |
CN113975402B (zh) * | 2021-07-19 | 2023-05-16 | 河南大学 | 靶向脑缺血区线粒体的神经保护药物ss31-ha-qt及其荧光探针和应用 |
CN116602952A (zh) * | 2023-03-28 | 2023-08-18 | 浙江大学 | 脂肪代谢因子lipoxinB4在制备动脉粥样硬化治疗药物中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1938042A (zh) * | 2004-01-23 | 2007-03-28 | 科内尔研究基金会 | 用于减轻氧化性损伤的方法 |
CN102791279A (zh) * | 2009-12-31 | 2012-11-21 | 康肽德生物医药技术有限公司 | 用于进行冠状动脉旁路移植手术的方法 |
CN104203262A (zh) * | 2012-02-23 | 2014-12-10 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
CN104324360A (zh) * | 2005-09-16 | 2015-02-04 | 科内尔研究基金会 | 用于减少cd36表达的方法 |
WO2016007921A1 (fr) * | 2014-07-10 | 2016-01-14 | Rhodel Island Hospital | Traitement de l'arythmie par antioxydants à ciblage mitochondrial |
CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3485897A1 (fr) * | 2012-08-02 | 2019-05-22 | Stealth Peptides International, Inc. | D-arg-2'6'-dmt-lys-phe-nh2 pour réduire les effets secondaires des statins |
-
2017
- 2017-03-24 CN CN201710186245.1A patent/CN107041946A/zh active Pending
- 2017-12-27 WO PCT/CN2017/118835 patent/WO2018171279A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1938042A (zh) * | 2004-01-23 | 2007-03-28 | 科内尔研究基金会 | 用于减轻氧化性损伤的方法 |
CN104324360A (zh) * | 2005-09-16 | 2015-02-04 | 科内尔研究基金会 | 用于减少cd36表达的方法 |
CN102791279A (zh) * | 2009-12-31 | 2012-11-21 | 康肽德生物医药技术有限公司 | 用于进行冠状动脉旁路移植手术的方法 |
CN104203262A (zh) * | 2012-02-23 | 2014-12-10 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
WO2016007921A1 (fr) * | 2014-07-10 | 2016-01-14 | Rhodel Island Hospital | Traitement de l'arythmie par antioxydants à ciblage mitochondrial |
CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
Non-Patent Citations (2)
Title |
---|
HAO, SHUANGYING: "Mitochondrion-Targeted Peptide SS-31 Inhibited Oxidi- zed Low-Density Lipoproteins-Induced Foam Cell Formation through both ROS Scavenging and Inhibition of Cholesterol Influx in RAW264.7 Cells", MOLECULES, vol. 20, no. 12, 1 December 2015 (2015-12-01), XP055610656 * |
ZHANG, MENG: "Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet", PLOS ONE, vol. 12A, no. 9, e0185688, 29 September 2017 (2017-09-29), pages 1 - 15, XP055610654 * |
Also Published As
Publication number | Publication date |
---|---|
CN107041946A (zh) | 2017-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018171279A1 (fr) | Application du composé ss-31 pour la préparation d'un médicament pour le traitement de l'athérosclérose et de maladies associées | |
Bi et al. | Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress | |
Meng et al. | Estrogen prevent atherosclerosis by attenuating endothelial cell pyroptosis via activation of estrogen receptor α-mediated autophagy | |
Kim et al. | Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4–MD2 complex | |
Rayner et al. | Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A | |
Kim et al. | TFEB–GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response | |
De Gaetano et al. | M1-and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis | |
Zhang et al. | Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver | |
Xing et al. | Salidroside decreases atherosclerosis plaque formation via inhibiting endothelial cell pyroptosis | |
Wang et al. | Protective effect of shikonin in experimental ischemic stroke: attenuated TLR4, p-p38MAPK, NF-κB, TNF-α and MMP-9 expression, up-regulated claudin-5 expression, ameliorated BBB permeability | |
Salazar et al. | Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells | |
Liu et al. | Sulconazole induces PANoptosis by triggering oxidative stress and inhibiting glycolysis to increase radiosensitivity in esophageal cancer | |
Petrović et al. | Oxidative stress-dependent contribution of HMGB1 to the interplay between apoptosis and autophagy in diabetic rat liver | |
Yaman et al. | Effects of resveratrol on incisional wound healing in rats | |
Wu et al. | C1QTNF1 attenuates angiotensin II-induced cardiac hypertrophy via activation of the AMPKa pathway | |
Song et al. | Essential role for UVRAG in autophagy and maintenance of cardiac function | |
Ren et al. | Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis | |
Wang et al. | κ-opioid receptor activation promotes mitochondrial fusion and enhances myocardial resistance to ischemia and reperfusion injury via STAT3-OPA1 pathway | |
Zheng et al. | SAP deficiency mitigated atherosclerotic lesions in ApoE−/− mice | |
Liu et al. | Irisin Attenuates Apoptosis Following Ischemia–Reperfusion Injury Through Improved Mitochondria Dynamics and ROS Suppression Mediated Through the PI3K/Akt/mTOR Axis | |
Wang et al. | Nuclear receptor subfamily 4 group A member 1 promotes myocardial ischemia/reperfusion injury through inducing mitochondrial fission factor-mediated mitochondrial fragmentation and inhibiting FUN14 domain containing 1-depedent mitophagy | |
Wang et al. | Blocking CXCR3 with AMG487 ameliorates the blood-retinal barrier disruption in diabetic mice through anti-oxidative | |
Li et al. | Role of mechanistic target of rapamycin and autophagy in alcohol-induced adipose atrophy and liver injury | |
Zhang et al. | SAP130 released by ferroptosis tubular epithelial cells promotes macrophage polarization via Mincle signaling in sepsis acute kidney injury | |
Nakladal et al. | Perivascular adipose tissue-derived nitric oxide compensates endothelial dysfunction in aged pre-atherosclerotic apolipoprotein E-deficient rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17902255 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17902255 Country of ref document: EP Kind code of ref document: A1 |